Related content

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

By Hart Warren Mark   Abrams Paul   Munro Vicki   Retsa Peny   Nazir Jameel  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1246-1254

Informa Healthcare

Access to resources Recommend Favorite

Solifenacin for the treatment of overactive bladder

By Robinson Dudley   Cardozo Linda  

Therapy, Vol. 8, Iss. 6, 2011-11 ,pp. : 691-701

Future Medicine

Access to resources Recommend Favorite

Comparative Effectiveness of Combined Low- and Standard-Dose Trospium and Solifenacin for Moderate Overactive Bladder Symptoms in Elderly Men and Women

By  

Urologia Internationalis, Vol. 93, Iss. 4, 2014-08 ,pp. : 470-473

Karger

Access to resources Recommend Favorite

Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes

By Mallett Veronica   Burks David   Garely Alan D.   Smith Neila  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 821-831

Informa Healthcare

Access to resources Recommend Favorite

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

By Speakman Mark   Khullar Vik   Mundy Anthony   Odeyemi Isaac   Bolodeoku John  

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2173-2179

Informa Healthcare

Access to resources Recommend Favorite